Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CVRx Inc (CVRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: CVRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11
1 Year Target Price $11
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 47.1% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 178.08M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 7 | Beta 1.25 | 52 Weeks Range 4.30 - 18.55 | Updated Date 07/12/2025 |
52 Weeks Range 4.30 - 18.55 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -97.49% | Operating Margin (TTM) -108.82% |
Management Effectiveness
Return on Assets (TTM) -26.88% | Return on Equity (TTM) -76.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 125831851 | Price to Sales(TTM) 3.37 |
Enterprise Value 125831851 | Price to Sales(TTM) 3.37 | ||
Enterprise Value to Revenue 2.38 | Enterprise Value to EBITDA -1.31 | Shares Outstanding 26072600 | Shares Floating 17884239 |
Shares Outstanding 26072600 | Shares Floating 17884239 | ||
Percent Insiders 4.26 | Percent Institutions 73.63 |
Upturn AI SWOT
CVRx Inc
Company Overview
History and Background
CVRx, Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota. The company is focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. CVRx went public in 2021. The company initially focused on treating hypertension but has expanded its focus to heart failure.
Core Business Areas
- Barostim Therapy for Heart Failure: CVRx's primary focus is its Barostim system for treating heart failure with reduced ejection fraction. This device stimulates baroreceptors in the carotid artery to modulate autonomic nervous system activity, improving heart function and reducing symptoms.
Leadership and Structure
The leadership team includes Nadim Yared (President and CEO), and a board of directors.
Top Products and Market Share
Key Offerings
- Barostim NEO System: The Barostim NEO system is CVRx's lead product. It is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery to treat heart failure. Market share data is unavailable. Competitors include companies offering alternative heart failure treatments, such as drug therapies from companies like Novartis (NVS) and Abbott (ABT) with their CardioMEMS HF system.
Market Dynamics
Industry Overview
The cardiovascular device market is a large and growing market, driven by the increasing prevalence of heart failure, hypertension, and other cardiovascular diseases. The industry is characterized by innovation, with companies constantly developing new and improved devices to treat these conditions.
Positioning
CVRx is positioned as a leader in neuromodulation therapy for heart failure. Its Barostim system offers a unique approach to treating heart failure by modulating the autonomic nervous system.
Total Addressable Market (TAM)
The TAM for heart failure therapies is significant, estimated to be in the billions of dollars. CVRx is positioned to capture a portion of this market with its Barostim system.
Upturn SWOT Analysis
Strengths
- Innovative neuromodulation technology
- FDA-approved device for heart failure
- Strong clinical evidence supporting Barostim's efficacy
Weaknesses
- Limited commercial presence
- High cost of therapy
- Dependence on a single product
Opportunities
- Expanding indications for Barostim
- Increasing awareness of neuromodulation therapy
- Partnerships with larger medical device companies
Threats
- Competition from established heart failure therapies
- Reimbursement challenges
- Potential for adverse events associated with Barostim
Competitors and Market Share
Key Competitors
- NVS
- ABT
- BSX
Competitive Landscape
CVRx's Barostim system offers a unique neuromodulation approach, but it faces competition from established drug therapies and devices offered by larger companies.
Growth Trajectory and Initiatives
Historical Growth: Historical revenue growth has been dependent on adoption rates of the Barostim system.
Future Projections: Analyst projections suggest continued revenue growth driven by increased adoption of Barostim and potential expansion into new markets.
Recent Initiatives: Recent initiatives include expanding the sales force and conducting clinical trials to support broader adoption of Barostim.
Summary
CVRx is a developing company with an innovative product for heart failure. While its Barostim system offers a unique approach and has shown promising results, the company faces challenges related to commercialization, reimbursement, and competition. Its future success depends on its ability to expand market adoption and demonstrate long-term clinical benefits. CVRX needs to monitor competitor offerings and reimbursement changes for its product to remain successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports (where available)
Disclaimers:
This analysis is based on publicly available information and limited financial data. It is not financial advice. Market share data is approximate and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CVRx Inc
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2021-06-30 | President, CEO & Director Mr. Kevin Hykes | ||
Sector Healthcare | Industry Medical Devices | Full time employees 206 | Website https://www.cvrx.com |
Full time employees 206 | Website https://www.cvrx.com | ||
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.